Search

Displaying results 2251 - 2260 of 4300 in total
  1. Drug

    Indapamide

    go.drugbank.com/drugs/DB00808
    ApprovedInvestigational

    [A204155] Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. … [A204134,A204161] Indapamide is characterized by both a methylindoline and a sulfamoyl chlorobenzamide functional group, with the former being largely responsible for the molecule’s lipid solubility

  2. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    It exerts its antiviral action by preventing RNA replication and virion assembly via binding to NS5A, a nonstructural phosphoprotein encoded by HCV. … Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  3. Drug

    Pegulicianine

    go.drugbank.com/drugs/DB18731
    ApprovedInvestigational

    [L50537] Pegulicianine (under the brand name Lumisight) was approved for use by the FDA in April 2024.[L50537,L50547] It received Fast Track and priority review for this indication.[L50547]

  4. Drug

    Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)

    go.drugbank.com/drugs/DB10991
    ApprovedInvestigational

    Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) is a vaccine that is used in the prophylaxis of Pertussis (whooping cough), which is caused by a small Gram-negative coccobacillus

  5. Drug

    Histrelin

    go.drugbank.com/drugs/DB06788
    ApprovedInvestigationalWithdrawn

    [L41715] Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. … [L41715] The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition.

  6. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    [L938] A month later, inotuzumab ozogamicin was also approved by the FDA.[L50542] … [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

  7. Drug

    Nadroparin

    go.drugbank.com/drugs/DB08813
    ApprovedInvestigationalWithdrawn

    Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa.

  8. Drug

    Tetrahydrocannabivarin

    go.drugbank.com/drugs/DB11755
    Investigational

    Δ9-THC is currently available in several synthetic forms, including [Dronabinol], while purified or isolated THCV is not approved for any medical uses and is not available as any marketed products. … Although THCV possesses an almost identical structure to Δ9-THC (varying only by the length of its lipophilic alkyl chain), it has different molecular targets and pharmacological profile [A32972].

  9. Drug

    Ropinirole

    go.drugbank.com/drugs/DB00268
    ApprovedInvestigational

    It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.

  10. Drug

    Human papillomavirus type 11 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10300
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces